Two ongoing, randomized, phase 3 trials are testing the safety and efficacy of pyrotinib and poziotinib compared to docetaxel in HER2 mutated advanced NSCLC in progression to first line platinum-based chemotherapy (NCT04447118, NCT05378763). Here, ERBB2 is linked to non-small cell lung carcinoma.